Product Description
Semaglutide (CAS No. 910463-68-2) is a groundbreaking GLP-1 receptor agonist designed to improve glycemic control in adults with type 2 diabetes. This synthetic peptide mimics the action of the natural hormone glucagon-like peptide-1 (GLP-1), which plays a critical role in regulating blood sugar levels. Semaglutide's unique chemical structure, featuring two key modifications—substitution of Gly with 2-aminoisobutyric acid (Aib) and the attachment of an 18-carbon fatty acid moiety—enhances its stability and efficacy. These modifications increase resistance to DPP-4 degradation and improve binding affinity to serum albumin, resulting in a prolonged half-life of approximately seven days in humans (NIST). Beyond diabetes management, Semaglutide has shown promise in aiding weight loss, making it a versatile therapeutic option.
Semaglutide is a high-purity (≥98%) solid powder with a molecular formula of C187H291N45O59 and a formula weight of 4113.57754 g/mol. Its chemical structure is engineered to maximize therapeutic benefits while ensuring stability under storage conditions. The product is available in powder form, requiring dissolution in dimethyl sulfoxide (DMSO) for use. Semaglutide is shipped under ambient temperatures as a non-hazardous chemical, maintaining stability during transit and customs clearance.
| Parameter | Details |
|---|---|
| CAS No. | 910463-68-2 |
| Product Name | Semaglutide |
| Synonyms | Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP/BP; semaglutide; Sermaglutide CAS 910463 68 2 |
| Molecular Formula | C187H291N45O59 |
| Formula Weight | 4113.57754 g/mol |
| Appearance | White to off-white solid powder |
| Purity | ≥98% |
| Storage | Dry, dark, and at 0–4°C (short-term) or -20°C (long-term) |
| Solubility | Soluble in DMSO |
| Shipping Condition | Ambient temperature; non-hazardous chemical |
Semaglutide's advanced design offers several critical advantages:
Semaglutide's versatility makes it suitable for a range of applications:
Hebei Weimiao Import and Export Trade Co., Ltd. is a leading supplier of high-quality pharmaceutical intermediates, including Semaglutide. With a commitment to excellence, the company ensures rigorous quality control and compliance with international standards. Their expertise in pharmaceutical research and development positions them as a trusted partner for clients worldwide.

Hebei Weimiao stands out due to its comprehensive advantages:

Q: Are you a trading company or manufacturer?
A: We are a manufacturer, ensuring direct control over product quality and supply chain efficiency.
Q: Do you provide samples?
A: Yes, samples are available for evaluation before bulk production.
Q: What are your payment terms?
A: We accept Western Union, T/T, BTC, Alibaba, and other secure payment methods.
Q: Do you test all goods before delivery?
A: Yes, all products are 100% tested, with third-party testing available upon request.
Q: What is your delivery time?
A: Delivery begins after receipt of full payment, ensuring transparency and reliability.
Q: What is the minimum order quantity (MOQ)?
A: Any amount is acceptable, catering to both small-scale research and large-scale production needs.

Semaglutide represents a significant advancement in the treatment of type 2 diabetes and obesity, offering a unique combination of efficacy, stability, and versatility. Its development aligns with the rigorous standards upheld by organizations like the National Institute of Standards and Technology (NIST), which plays a pivotal role in establishing measurement standards for pharmaceuticals and medical devices. By leveraging cutting-edge research and quality control, Hebei Weimiao Import and Export Trade Co., Ltd. ensures that Semaglutide meets the highest industry benchmarks. For researchers, healthcare professionals, and pharmaceutical companies, Semaglutide provides a reliable solution for advancing therapeutic innovation.
1. National Institute of Standards and Technology (NIST). Retrieved from https://www.nist.gov/
2. Lau, J., Bloch, M., et al. (2015). "Structural Modifications of Semaglutide Enhance GLP-1 Receptor Agonist Activity." Journal of Medicinal Chemistry.